| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1850 | 2020 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1717 | 2020 |
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1573 | 2014 |
| Apalutamide for metastatic, castration-sensitive prostate cancer KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ... New England Journal of Medicine 381 (1), 13-24, 2019 | 1240 | 2019 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1046 | 2016 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1040 | 2013 |
| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 581 | 2020 |
| Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, S Bhayani, WP Bro, SS Chang, ... Journal of the National Comprehensive Cancer Network 15 (6), 804-834, 2017 | 564 | 2017 |
| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 523 | 2020 |
| Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 507 | 2014 |
| Kidney cancer RJ Motzer, N Agarwal, C Beard, GB Bolger, B Boston, MA Carducci, ... Journal of the National Comprehensive Cancer Network 7 (6), 618-630, 2009 | 428 | 2009 |
| Advances in bladder cancer biology and therapy L Tran, JF Xiao, N Agarwal, JE Duex, D Theodorescu Nature Reviews Cancer 21 (2), 104-121, 2021 | 427 | 2021 |
| Bladder cancer PE Clark, N Agarwal, MC Biagioli, MA Eisenberger, RE Greenberg, ... Journal of the National Comprehensive Cancer Network 11 (4), 446-475, 2013 | 413 | 2013 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 370 | 2022 |
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first … JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ... The lancet oncology 16 (3), 293-300, 2015 | 369 | 2015 |
| Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ... Journal of Clinical Oncology 34 (18), 2098-2106, 2016 | 360 | 2016 |
| TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint … ST Tagawa, AV Balar, DP Petrylak, AR Kalebasty, Y Loriot, A Fléchon, ... Journal of Clinical Oncology 39 (22), 2474, 2021 | 351 | 2021 |
| Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant … A Goldkorn, B Ely, DI Quinn, CM Tangen, LM Fink, T Xu, P Twardowski, ... Journal of clinical oncology 32 (11), 1136, 2014 | 330 | 2014 |
| Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study KN Chi, S Chowdhury, A Bjartell, BH Chung, ... Journal of Clinical Oncology 39 (20), 2294-2303, 2021 | 322 | 2021 |
| Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma RJ Motzer, TE Hutson, MR Olsen, GR Hudes, JM Burke, WJ Edenfield, ... J Clin Oncol 30 (12), 1371-1377, 2012 | 305 | 2012 |
